Breaking News Instant updates and real-time market news.

CPRX

Catalyst Pharmaceuticals

$6.11

0.06 (0.99%)

08:03
05/07/19
05/07
08:03
05/07/19
08:03

Catalyst's Firdapse faces competition from Jacobus drug, STATNews reports

The Food & Drug Administration's "surprise" approval of a medication from Jacobus Pharmaceuticals for Lambert-Eaton myasthenic syndrome, or LEMS, for children ages 6 to 17, could potentially add unforeseen competition for Catalyst Pharmaceuticals, which last December won an FDA endorsement to market Firdapse, its own treatment for adults, STATNews' Ed Silverman reports. The list price for Firdapse is $375,000 while, prior to the approval, a few hundred LEMS patients were able for years to obtain the Jacobus drug for free under a compassionate use program sanctioned by the FDA. Jacobus has not yet disclosed a price for its drug, called Ruzurgi. Shares of Catalyst Pharmaceuticals are down about 37% in pre-market trading. Reference Link

  • 13

    May

  • 23

    May

CPRX Catalyst Pharmaceuticals
$6.11

0.06 (0.99%)

03/19/19
PIPR
03/19/19
NO CHANGE
Target $7.5
PIPR
Overweight
Catalyst comments point toward strong Firdapse launch, says Piper Jaffray
Shares of Catalyst Pharmaceuticals are trading higher after the company's Q4 earnings call and comments from management that point toward a strong Firdapse launch, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Accrual of former EAP patients onto Catalyst Pathways has been quicker than expected and payer interactions appear to be progressing nicely, adds the analyst. He views his $41.0M 2019 sales estimate as "readily achievable" and maintains an Overweight rating on Catalyst Pharmaceuticals with a $7.50 price target.
03/19/19
HCWC
03/19/19
NO CHANGE
HCWC
Catalyst's initial launch of Firdapse 'strong,' says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $9 price target on Catalyst Pharmaceuticals, saying the initial look at the Firdapse commercial launch suggests "healthy momentum" and "strong execution" on the part of the company. The analyst also noted that Firdapse is also being investigated in two Phase 3 trials for the treatment of anti-MuSK antibody positive myasthenia gravis and congenital myasthenic syndromes, with both trials planned to read out in the second half of 2019.
05/06/19
PIPR
05/06/19
NO CHANGE
Target $7.5
PIPR
Overweight
Ruzurgi approval to pressure Catalyst Pharmaceuticals, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $7.50 price target on Catalyst Pharmaceuticals but warned that the stock could come under pressure after the FDA's "unexpected" approval of Jacobus' amifampridine, or Ruzurgi, for the treatment of pediatric LEMS patients. Shares of Catalyst Pharmaceuticals were down over 41% after hours, and the analyst expressed uncertainty over whether the company's Firdapse would be able to maintain the orphan drug price point set at launch. Catanzaro expects the management of Catalyst Pharmaceuticals to comment on the development.
05/07/19
CANT
05/07/19
NO CHANGE
Target $10
CANT
Overweight
Jacobus approval should not impact Catalyst's Firdapse, says Cantor Fitzgerald
The FDA last night approved private company Jacobus' Ruzurgi for the treatment of Lambert-Eaton myasthenic syndrome in patients six to less than 17 years of age, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. This is the first drug approved for pediatric LEMS, the analyst points out. Catalyst Pharmaceuticals' slightly different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only, he notes. The analyst does not see the approval of Ruzurgi as having a large impact in Firdapse's market potential. He estimates that the pediatric population consists of less than 5% of the prevalent LEMS population. Duncan reiterates an Overweight rating on Catalyst shares with a $10 price target.

TODAY'S FREE FLY STORIES

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47
Hot Stocks
Novartis says wholesale acquisition cost of Zolgensma $2.125M »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TIVO

TiVo

$6.87

0.04 (0.59%)

12:45
05/24/19
05/24
12:45
05/24/19
12:45
Options
TiVo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

12:45
05/24/19
05/24
12:45
05/24/19
12:45
General news
Breaking General news story  »

Week of 5/24 Baker-Hughes…

VWAGY

Volkswagen

$0.00

(0.00%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Appeals court rules in favor of Volkswagen diesel car owners, Reuters reports »

A German appeals court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$56.30

0.85 (1.53%)

, WCG

WellCare

$267.57

-6.89 (-2.51%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Third Point confirms Centene stake to CNBC, says WellCare deal in best interest »

CNBC tweeted: "Third…

CNC

Centene

$56.30

0.85 (1.53%)

WCG

WellCare

$267.57

-6.89 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

, IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

12:40
05/24/19
05/24
12:40
05/24/19
12:40
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows for the past week…

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

XLK

Technology Select Sector SPDR

$73.62

0.33 (0.45%)

SMH

Market Vectors Semiconductor

$100.37

0.23 (0.23%)

SOXX

iShares PHLX Semiconductor ETF

$180.13

0.06 (0.03%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.60

0.14 (0.12%)

EEM

iShares MSCI Emerging Markets ETF

$40.00

0.08 (0.20%)

XLU

Utilities SPDR

$59.99

0.07 (0.12%)

XLV

Health Care Select Sector SPDR

$89.56

0.17 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$126.65

0.46 (0.36%)

, CCOEY

Capcom

$0.00

(0.00%)

12:37
05/24/19
05/24
12:37
05/24/19
12:37
Hot Stocks
Microsoft says Project xCloud can stream more than 3,500 games »

Kareem Choudhry,…

MSFT

Microsoft

$126.65

0.46 (0.36%)

CCOEY

Capcom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

NVS

Novartis

$86.93

2.47 (2.92%)

12:33
05/24/19
05/24
12:33
05/24/19
12:33
Hot Stocks
Novartis announces FDA approval for Zolgensma »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CNC

Centene

$55.37

-0.08 (-0.14%)

, WCG

WellCare

$273.18

-1.28 (-0.47%)

12:33
05/24/19
05/24
12:33
05/24/19
12:33
Periodicals
Third Point thinks Centene should consider sale before buying WellCare, WSJ says »

Daniel Loeb's Third…

CNC

Centene

$55.37

-0.08 (-0.14%)

WCG

WellCare

$273.18

-1.28 (-0.47%)

HUM

Humana

$262.97

3.1 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 05

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

  • 13

    Nov

NVS

Novartis

$86.95

2.49 (2.95%)

12:31
05/24/19
05/24
12:31
05/24/19
12:31
Hot Stocks
Breaking Hot Stocks news story on Novartis »

Novartis announces FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

KNX

Knight-Swift

$29.75

-0.65 (-2.14%)

12:30
05/24/19
05/24
12:30
05/24/19
12:30
Options
Volatility play opened in Knight Transportation »

Volatility play opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 13

    Nov

WCG

WellCare

$273.55

-0.91 (-0.33%)

, CNC

Centene

$55.41

-0.04 (-0.07%)

12:27
05/24/19
05/24
12:27
05/24/19
12:27
Periodicals
Breaking Periodicals news story on WellCare, Centene »

Activist Third Point has…

WCG

WellCare

$273.55

-0.91 (-0.33%)

CNC

Centene

$55.41

-0.04 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

WCG

WellCare

$273.55

-0.91 (-0.33%)

, CNC

Centene

$55.41

-0.04 (-0.07%)

12:26
05/24/19
05/24
12:26
05/24/19
12:26
Periodicals
Breaking Periodicals news story on WellCare, Centene »

Third Point thinks…

WCG

WellCare

$273.55

-0.91 (-0.33%)

CNC

Centene

$55.41

-0.04 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

FLEX

Flex

$9.39

-0.08 (-0.84%)

12:25
05/24/19
05/24
12:25
05/24/19
12:25
Periodicals
Huawei phone assembler Flex stops production at China factory, NAR says »

Flex, Huawei's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$357.37

6.8 (1.94%)

12:23
05/24/19
05/24
12:23
05/24/19
12:23
Periodicals
SEC probing Boeing disclosures on grounded 737 Max, Bloomberg reports »

The SEC is investigating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SNA

Snap-On

$157.57

0.25 (0.16%)

12:20
05/24/19
05/24
12:20
05/24/19
12:20
Options
Bullish call spread in Snap On will create its biggest open interest »

Bullish call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
05/24/19
05/24
12:17
05/24/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
05/24/19
05/24
12:16
05/24/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$358.20

7.63 (2.18%)

, SMI

SMIC

$5.18

-0.315 (-5.74%)

12:13
05/24/19
05/24
12:13
05/24/19
12:13
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are finishing out…

BA

Boeing

$358.20

7.63 (2.18%)

SMI

SMIC

$5.18

-0.315 (-5.74%)

FL

Foot Locker

$44.14

-8.705 (-16.47%)

HPQ

HP Inc.

$20.06

0.865 (4.51%)

HPE

HP Enterprise

$14.64

0.31 (2.16%)

TSS

TSYS

$110.03

10.42 (10.46%)

GPN

Global Payments

$152.60

4.63 (3.13%)

HIBB

Hibbett Sports

$24.25

4.405 (22.20%)

DVAX

Dynavax

$5.33

-1.03 (-16.20%)

SPLK

Splunk

$117.39

-11.29 (-8.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 09

    Jul

  • 09

    Jul

  • 13

    Nov

ACHC

Acadia

$32.58

0.35 (1.09%)

12:13
05/24/19
05/24
12:13
05/24/19
12:13
Conference/Events
Acadia to hold a strategic update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BA

Boeing

$357.94

7.365 (2.10%)

12:12
05/24/19
05/24
12:12
05/24/19
12:12
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing off highs, still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

BA

Boeing

$357.77

7.2 (2.05%)

12:12
05/24/19
05/24
12:12
05/24/19
12:12
Periodicals
Breaking Periodicals news story on Boeing »

SEC probing Boeing over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SWKS

Skyworks

$69.32

0.77 (1.12%)

12:10
05/24/19
05/24
12:10
05/24/19
12:10
Options
Call buyer loading up on Skyworks July 70s »

Call buyer loading up on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

TSS

TSYS

$109.69

10.08 (10.12%)

, GPN

Global Payments

$152.48

4.51 (3.05%)

12:09
05/24/19
05/24
12:09
05/24/19
12:09
Periodicals
Global Payments near deal to acquire TSYS for $20B in stock, CNBC reports »

Global Payments (GPN) is…

TSS

TSYS

$109.69

10.08 (10.12%)

GPN

Global Payments

$152.48

4.51 (3.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 05

    Jun

  • 13

    Nov

ESV

Ensco Rowan

$8.56

-0.285 (-3.22%)

12:05
05/24/19
05/24
12:05
05/24/19
12:05
Options
Ensco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.